These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 10394300)

  • 1. [Human resistance to generalized bacterial infections (exemplified by meningococcal infection)].
    Platonov AE
    Vestn Ross Akad Med Nauk; 1999; (5):40-5. PubMed ID: 10394300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum bactericidal antibody assays - The role of complement in infection and immunity.
    McIntosh ED; Bröker M; Wassil J; Welsch JA; Borrow R
    Vaccine; 2015 Aug; 33(36):4414-21. PubMed ID: 26187262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A generic mechanism in Neisseria meningitidis for enhanced resistance against bactericidal antibodies.
    Uria MJ; Zhang Q; Li Y; Chan A; Exley RM; Gollan B; Chan H; Feavers I; Yarwood A; Abad R; Borrow R; Fleck RA; Mulloy B; Vazquez JA; Tang CM
    J Exp Med; 2008 Jun; 205(6):1423-34. PubMed ID: 18504306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naturally acquired passive protective activity against Neisseria meningitidis Group C in the absence of serum bactericidal activity.
    Welsch JA; Granoff D
    Infect Immun; 2004 Oct; 72(10):5903-9. PubMed ID: 15385492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal disease.
    Granoff DM
    Vaccine; 2009 Jun; 27 Suppl 2(Suppl 2):B117-25. PubMed ID: 19477054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meningococcal surrogates of protection--serum bactericidal antibody activity.
    Borrow R; Balmer P; Miller E
    Vaccine; 2005 Mar; 23(17-18):2222-7. PubMed ID: 15755600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease.
    Frasch CE; Borrow R; Donnelly J
    Vaccine; 2009 Jun; 27 Suppl 2():B112-6. PubMed ID: 19464093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The bactericidal action of human neutrophils on meningococci in vitro].
    Platonov AE; Vershinina IV; Käyhty H; Fijen CA; Kuijper EJ
    Zh Mikrobiol Epidemiol Immunobiol; 1999; (3):46-52. PubMed ID: 10851990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Importance of complement source in measuring meningococcal bactericidal titers.
    Santos GF; Deck RR; Donnelly J; Blackwelder W; Granoff DM
    Clin Diagn Lab Immunol; 2001 May; 8(3):616-23. PubMed ID: 11329468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum factors and polymorphonuclear leukocytes in human host defence against Neisseria meningitidis. Studies of interactions with special reference to a chemiluminometric technique.
    Fredlund H
    Scand J Infect Dis Suppl; 1993; 87():1-72. PubMed ID: 8511525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of natural immunity to Neisseria meningitidis.
    Pollard AJ; Frasch C
    Vaccine; 2001 Jan; 19(11-12):1327-46. PubMed ID: 11163654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antibody response in subjects with meningococal disease and in healthy carriers of Neisseria meningitidis].
    Natoli D; Tringali G; Puma G; Castellini S; Chiarini A
    G Batteriol Virol Immunol; 1976; 69(1-6):64-70. PubMed ID: 828887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complement deficiency states and meningococcal disease.
    Figueroa J; Andreoni J; Densen P
    Immunol Res; 1993; 12(3):295-311. PubMed ID: 8288947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of Fcgamma receptor polymorphisms and C3 in the immune defence against Neisseria meningitidis in complement-deficient individuals.
    Fijen CA; Bredius RG; Kuijper EJ; Out TA; De Haas M; De Wit AP; Daha MR; De Winkel JG
    Clin Exp Immunol; 2000 May; 120(2):338-45. PubMed ID: 10792385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interactions between Neisseria meningitidis and the complement system.
    Schneider MC; Exley RM; Ram S; Sim RB; Tang CM
    Trends Microbiol; 2007 May; 15(5):233-40. PubMed ID: 17398100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Detection of individuals within a group of risk for meningococcal infection morbidity in organized collectives].
    Efimov EI; Dulatora MV; Pospelov VF
    Zh Mikrobiol Epidemiol Immunobiol; 1990 Sep; (9):40-3. PubMed ID: 2124024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Seroprevalence of Antibody-Mediated, Complement-Dependent Opsonophagocytic Activity against Neisseria meningitidis Serogroup B in England.
    Humphries HE; Brookes C; Allen L; Kuisma E; Gorringe A; Taylor S
    Clin Vaccine Immunol; 2015 May; 22(5):503-9. PubMed ID: 25739917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of complement in anti-bacterial defence.
    D'Amelio R; Biselli R
    Ann Ital Med Int; 1994; 9(3):173-7. PubMed ID: 7946895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meningococcal disease and the complement system.
    Lewis LA; Ram S
    Virulence; 2014 Jan; 5(1):98-126. PubMed ID: 24104403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human immunity to the meningococcus. I. The role of humoral antibodies.
    Goldschneider I; Gotschlich EC; Artenstein MS
    J Exp Med; 1969 Jun; 129(6):1307-26. PubMed ID: 4977280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.